References

1. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315 [CrossRef] [Google Scholar] [PubMed]
2. Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347: 1175-1186 [CrossRef] [Google Scholar] [PubMed]
3. Malfertheiner P, Chan FK, McColl KE (2009) Peptic ulcer disease. Lancet 374: 1449-1461 [CrossRef] [Google Scholar] [PubMed]
4. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection.Am J Gastroenterol 102: 1808-1825 [CrossRef] [Google Scholar] [PubMed]
5. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al. (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.J Gastroenterol Hepatol 24: 1587-1600 [CrossRef] [Google Scholar] [PubMed]
6. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, et al. (2012) Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 61: 646-664 [CrossRef] [Google Scholar] [PubMed]
7. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY (2000) Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45: 68-76 [CrossRef] [Google Scholar] [PubMed]
8. Mégraud F (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374-1384 [CrossRef] [Google Scholar] [PubMed]
9. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, et al. (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62: 34-42 [CrossRef] [Google Scholar] [PubMed]
10. Wolle K, Leodolter A, Malfertheiner P, König W (2002) Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 51: 705-709 [CrossRef] [Google Scholar] [PubMed]
11. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, et al. (2001) Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 39: 2677-2680 [CrossRef] [Google Scholar] [PubMed]
12. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, et al. (2002) The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7: 306-309 [CrossRef] [Google Scholar] [PubMed]
13. Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance.Gut 59: 1143-1153 [CrossRef] [Google Scholar] [PubMed]
14. Vakil N, Vaira D (2013) Treatment for H. pylori infection: new challenges with antimicrobial resistance.J Clin Gastroenterol 47: 383-388 [CrossRef] [Google Scholar] [PubMed]
15. Rimbara E, Fischbach LA, Graham DY (2011) Optimal therapy for Helicobacter pylori infections.Nat Rev Gastroenterol Hepatol 8: 79-88 [CrossRef] [Google Scholar] [PubMed]
16. Graham DY, Lee YC, Wu MS (2014) Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 12: 177-186 [CrossRef] [Google Scholar] [PubMed]
17. Heep M, Kist M, Strobel S, Beck D, Lehn N (2000) Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19: 538-541 [CrossRef] [Google Scholar] [PubMed]
18. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, et al. (2002) High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure helicobacter pylori infection: Impact of two secondline therapies in a randomized study. Aliment Pharmacol Ther 16: 315-324 [CrossRef] [Google Scholar] [PubMed]
19. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, et al. (2015) High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.Clin Gastroenterol Hepatol 13: 895-905 [CrossRef] [Google Scholar] [PubMed]
20. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG (2006) Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.Lancet Infect Dis 6: 699-709 [CrossRef] [Google Scholar] [PubMed]
21. Camargo MC, García A, Riquelme A, Otero W, Camargo CA, et al. (2014) The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 109: 485-495 [CrossRef] [Google Scholar] [PubMed]
22. Marshall BJ, Valenzuela JE, McCallum RW, Dooley CP, Guerrant RL, et al. (1993) Bismuth subsalicylate suppression of helicobacterpylori in nonulcer dyspepsia: A double-blind placebo-controlled trial. Dig Dis Sci 38:1674- 1680 [CrossRef] [Google Scholar] [PubMed]
23. Konturek SJ, Radecki T, Piastucki I, Drozdowicz D (1986) Advances in the understanding of the mechanism of cytoprotective action by colloidal bismuth subcitrate.Scand J Gastroenterol Suppl 122: 6-10 [CrossRef] [Google Scholar] [PubMed]
24. Lambert JR (1991) Clinical indications and efficacy of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl 185: 13-21 [CrossRef] [Google Scholar] [PubMed]
25. Bradley B, Singleton M, Lin Wan Po A (1989) Bismuth toxicity--a reassessment. J Clin Pharm Ther 14: 423-441 [CrossRef] [Google Scholar] [PubMed]
26. Mohan R (2010) Green bismuth. Nat Chem 2: 336 [CrossRef] [Google Scholar] [PubMed]
27. Scarpignato C, Pelosini I (1999) Bismuth compounds for eradication of helicobacter pylori: Pharmacology and safety. Clinical Pharmacology and Therapy of Helicobacter pylori Infection Prog Basic Clin Pharmacol Basel, Switzerland: Karger 11:87-127 [CrossRef]
28. Lambert JR, Midolo P (1997) The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 11 Suppl 1: 27-33 [CrossRef] [Google Scholar] [PubMed]
29. Stratton CW, Warner RR, Coudron PE, Lilly NA (1999) Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother 43: 659-666 [CrossRef] [Google Scholar] [PubMed]
30. Lambert JR, Hanksky J, Davidson A, Pinkard K, Stockman K (1985) Campylobacter like organisms (clo) in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy. Gastroenterology 88:1462
31. Andreasen JJ, Andersen LP (1987) In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol Microbiol Immunol Scand B 95: 147-149 [CrossRef] [Google Scholar] [PubMed]
32. Armstrong JA, Wee SH, Goodwin CS, Wilson DH (1987) Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study. J Med Microbiol 24: 343-350 [CrossRef] [Google Scholar] [PubMed]
33. Slomiany BL, Kasinathan C, Slomiany A (1989) Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol). Am J Gastroenterol 84: 1273-1277 [Google Scholar] [PubMed]
34. Nilius M, Ströhle A, Bode G, Malfertheiner P (1993) Coccoid like forms (CLF) of Helicobacter pylori. Enzyme activity and antigenicity. Zentralbl Bakteriol 280: 259-272 [CrossRef] [Google Scholar] [PubMed]
35. Goodwin CS, Armstrong JA, Cooper M. (1991) Colloidal bismuth subcitrate inhibits the adherence of h. Pylori to epithelial cells. Ital J Gastroenterol (suppl 2) 23:40
36. Nilius M, Schieffer S, Malfertheiner P (1992) Inhibition of h. Pylori adhesion to human smc by cbs and different proteaases. Ir J Med Sci (Suppl 10) 161:10
37. Marcus EA, Sachs G, et al. (2015) Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growthdependent antibiotics. Aliment Pharmacol Ther 42: 922-933 [CrossRef] [Google Scholar] [PubMed]
38. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH (1987) Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 37 Suppl 2: 16-30 [CrossRef] [Google Scholar] [PubMed]
39. Chiba N, Rao BV, Rademaker JW, Hunt RH (1992) Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87: 1716-1727 [Google Scholar] [PubMed]
40. George LL, Borody TJ, Andrews P, Devine M, Moore-Jones D, et al. (1990) Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 153: 145-149 [CrossRef] [Google Scholar] [PubMed]
41. Borody TJ, Cole P, Noonan S, Morgan A, Lenne J, et al. (1989) Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 151: 431-435 [CrossRef] [Google Scholar] [PubMed]
42. [No authors listed](1994) NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272: 65-69 [Google Scholar]
43. Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, et al. (1992) Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6: 427-435 [CrossRef] [Google Scholar] [PubMed]
44. Rautelin H, Seppälä K, Renkonen OV, Vainio U, Kosunen TU (1992) Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 36: 163-166 [CrossRef] [Google Scholar] [PubMed]
45. Glupczynski Y, Burette A, De Koster E, Nyst JF, Deltenre M, et al. (1990) Metronidazole resistance in Helicobacter pylori. Lancet 335: 976-977
46. Hosking SW, Ling TK, Yung MY, Cheng A, Chung SC, et al. (1992) Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 305: 502-504 [CrossRef] [Google Scholar] [PubMed]
47. de Boer W, Driessen W, Jansz A, Tytgat G (1995) Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345: 817- 820 [CrossRef] [Google Scholar] [PubMed]
48. Group EHPS (1997) Current european concepts in the management of helicobacter pylori infection. The maastricht consensus report. Gut 41: 8-13 [CrossRef] [Google Scholar] [PubMed]
49. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, et al. (2002) Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167- 180 [CrossRef] [Google Scholar] [PubMed]
50. Fischbach LA, van Zanten S, Dickason J (2004) Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 20: 1071-1082 [CrossRef] [Google Scholar] [PubMed]
51. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, et al. (2003) Bismuthbased quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 98: 562-567 [CrossRef] [Google Scholar] [PubMed]
52. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguère M, et al. (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, noninferiority, phase 3 trial. Lancet 377: 905-913 [CrossRef] [Google Scholar] [PubMed]
53. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781 [CrossRef] [Google Scholar] [PubMed]
54. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP5, et al. (2016) The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 151: 51-69 [CrossRef] [Google Scholar] [PubMed]
55. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P (2013) Metaanalysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 88: 33-45 [CrossRef] [Google Scholar] [PubMed]
56. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R (2014) Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 40: 171-177 [CrossRef] [Google Scholar] [PubMed]
57. O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, et al. (2003) Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 17: 415-420 [CrossRef] [Google Scholar] [PubMed]
58. Irie Y, Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K (1997) Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. J Antimicrob Chemother 40: 235-240 [CrossRef] [Google Scholar] [PubMed]
59. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJ (1996) Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J Bacteriol 178: 4822-4829 [CrossRef] [Google Scholar]
60. Lamp KC, Freeman CD, Klutman NE, Lacy MK (1999) Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36: 353-373 [CrossRef] [Google Scholar] [PubMed]